
Ossium Health Inc Profile last edited on: 9/26/2022
CAGE: 7QL09
UEI: FFNHJ2RDRHW3
Business Identifier: Bone marrow bank to treat blood cancers Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
1121 Howard Sttreet
San Francisco, CA 94103
San Francisco, CA 94103
(415) 513-5535 |
info@ossiumhealth.com |
www.ossiumhealth.com |
Location: Single
Congr. District: 12
County: San Francisco
Congr. District: 12
County: San Francisco
Public Profile
The management of Ossium define their mission as improving human health by driving niotechnology innovation that fosters the preservation of life. At its core, the firm's objective is anchored in the understanding that cells of the immune system are the human bodys natural defenders against disease. The objective therefore is to develop better methods of recovering, preserving, and deploying these critical cells that serve to keep disease at bay. Soecifically, to address the shortage of life-saving stem cells for transplant - to match the needs of hundreds of thousands iof patients - Ossium Health is building what could be the worlds bone marrow bank. Every year, new patients with sickle cell, leukemia, lymphoma, etc, need hematopoietic stem cell transplants to survive -- an estimated $20B market in US alone. These transplants are among the most powerful medical procedures - involving the replacement of someones entire blood and immune systems. There is a major shortage of the relevent bone marrow. Consequence: long wait-list in the US with almost 2/3rds dying before receiving a matched transplant. Ossium is focused on addressing this shortage by building a global bone marrow bank from previously untapped sources.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
10-14Revenue Range
1M-1.5MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
15-19Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
1741777963 | 2 | NIH | $375,114 | |
Project Title: Developing a bank of purified myeloid progenitor cells as a bridging therapy for transient pancytopenia resulting from radiation injury | ||||
2021 | 1 | NIH | $248,452 | |
Project Title: A novel approach to Mesenchymal Stem Cell Transduction | ||||
2021 | 1 | NIH | $224,453 | |
Project Title: Reducing a major cost burden of therapeutic cell manufacturing by selectivelyremoving toxic culture byproducts to allow recycling of media | ||||
2021 | 2 | NIH | $299,950 | |
Project Title: A Novel and Clinically Feasible Co-therapy of Deceased Donor Bone Marrow Combined With Donor-Matched Mesenchymal Stem Cells to Establish Immune Tolerance | ||||
2021 | 2 | NIH | $1,690,924 | |
Project Title: Novel Strategies for Storage and Recovery of Cadaveric Bone Marrow Stem Cells |
Key People / Management
Kevin Caldwell -- Co-Founder, President & CEO
Erik J Woods -- Co-Founder; Chief Executive Officer; President
Emily Hopewell
Brian H Johnstone
Aubrey Sherry -- Cellular Therapy Technologis
Bram Sterling -- Research Fellow
Erik J Woods -- Co Founder and Chief Science Officer
Erik J Woods -- Co-Founder; Chief Executive Officer; President
Emily Hopewell
Brian H Johnstone
Aubrey Sherry -- Cellular Therapy Technologis
Bram Sterling -- Research Fellow
Erik J Woods -- Co Founder and Chief Science Officer
Company News
There are no news available.